Core Viewpoint - PreveCeutical Medical Inc. has received approval for its Canadian Patent Application No. 3127020, which pertains to a cyclic peptide aimed at pain management, marking a significant milestone in the company's pain therapy program [1][3]. Patent Details - The patent application focuses on novel cyclized peptides that are analogues of dynorphin, designed to provide effective pain relief while minimizing adverse effects associated with traditional opioids [2]. - The patent is co-owned with The University of Queensland and is expected to be granted in Q2 2026, providing exclusivity in Canada until January 2040, with additional applications pending in the U.S., Europe, and Australia [3]. Technology and Development - PreveCeutical's pain therapy program aims to develop next-generation peptide-based analgesics that address the limitations of conventional opioids through advanced peptide engineering and cyclization techniques [4]. - The company is committed to pioneering safer alternatives to opioids, reinforcing its position in a market that increasingly demands such solutions [5]. Company Overview - PreveCeutical is a health sciences company focused on innovative preventive and curative therapies, with multiple research and development programs targeting various health issues, including non-addictive analgesic peptides [6].